文献速递头颈外科

经口手术治疗HPV相关口咽癌单淋巴结转移患者的结局

Outcomes of Patients With Single-Node Metastasis of Human Papillomavirus-Related Oropharyngeal Cancer Treated With Transoral Surgery.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2021-01-01

这项回顾性队列研究分析了207例p16阳性口咽鳞状细胞癌且病理确诊单淋巴结转移的成人患者,均接受经口手术伴或不伴辅助治疗。中位随访36.2个月,区域复发率5%,5年总生存率95%(95%CI 89%-98%)。辅助治疗与区域复发减少相关,区域复发患者挽救治疗成功率高。

要点

  • 单淋巴结转移的HPV相关口咽癌经口手术后预后良好,5年总生存率95%。
  • 辅助治疗与区域复发风险降低独立相关(OR 0.08,95%CI 0.02-0.4)。
  • 区域复发后挽救治疗成功率高,多数患者仍可治愈。

核心结论

  • HPV相关口咽癌单淋巴结转移患者接受经口手术伴或不伴辅助治疗生存极佳,辅助治疗改善区域控制。
  • 区域复发患者挽救治疗成功率高。

研究设计与样本

  • 回顾性队列研究纳入207例成人新诊断p16阳性口咽鳞状细胞癌且病理确诊单淋巴结转移患者。
  • 患者于2007年1月1日至2016年12月31日在2家三级学术医疗中心接受手术治疗。
  • 干预措施为单纯手术(n=59)、手术加辅助放疗(n=75)或手术加辅助放化疗(n=73)。

主要发现

  • 中位随访36.2个月(范围7-127个月),区域复发11例(5%),任何复发21例(10%)。
  • 任何复发中局部复发4例(19%)、区域复发11例(52%)、远处转移6例(29%)。
  • 5年总生存率95%(95%CI 89%-98%)。
  • 区域复发危险因素包括年龄较大(OR 1.2,95%CI 1.1-1.2)、晚期T分期(OR 3.5,95%CI 0.9-14.0)和切缘阳性(OR 10.9,95%CI 1.8-67.5)。
  • 淋巴结外扩展(OR 0.2,95%CI 0.04-0.8)、淋巴结大小>3cm(OR 0.2,95%CI 0.1-0.7)和辅助治疗(OR 0.08,95%CI 0.02-0.4)与区域复发减少相关。

关键数值与推荐

  • 区域复发11例中9例(82%)接受根治性治疗,最终7例挽救治疗成功,3例死于疾病。

临床怎么用

  • 对于HPV相关口咽癌单淋巴结转移患者,经口手术是可行的治疗选择,生存结局优秀。
  • 辅助治疗可显著降低区域复发风险,应考虑用于高风险患者。
  • 区域复发后积极挽救治疗仍可获得较高成功率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Regional lymph node metastasis remains an important prognostic factor in patients with oropharyngeal squamous cell carcinoma (OPSCC). Although survival among patients with regional metastasis in human papillomavirus (HPV)-related OPSCC is more favorable compared with patients who are HPV negative, prognostic variables associated with failure in patients with single-node metastasis are not known. OBJECTIVE: To evaluate recurrence and survival in patients with HPV-related OPSCC with single-lymph node metastasis treated with transoral surgery. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted of 207 adults with newly diagnosed p16-positive OPSCC and pathology-confirmed single-node disease who underwent surgical resection with or without adjuvant therapy at 2 tertiary academic medical centers from January 1, 2007, to December 31, 2016. Statistical analysis was performed from September 1, 2018, to September 1, 2020. INTERVENTIONS: Surgery alone (n = 59), surgery with adjuvant radiation (n = 75), or surgery with adjuvant chemoradiation (n = 73). MAIN OUTCOMES AND MEASURES: The primary outcome was regional recurrence. Secondary outcomes included overall survival, any recurrence, and identification of factors associated with regional recurrence and overall survival. RESULTS: Among 207 patients, 178 (86%) were men, with a median age of 57 years (range, 35-82 years) at the time of surgery. Median follow-up was 36.2 months (range, 7-127 months). Regional recurrence occurred in 11 patients (5%). Of these, 1 patient (9%) was lost to follow-up after diagnosis, 1 (9%) was treated with palliative chemotherapy, and 9 (82%) were treated with curative intent. Ultimately, 7 patients received successful salvage treatment, and 3 died with disease. Overall, there were 21 patients (10%) with any recurrence, with 4 patients (19%) experiencing local recurrence, 11 (52%) experiencing regional recurrence, and 6 (29%) experiencing distant metastasis. The 5-year overall survival was 95% (95% CI, 89%-98%) for all patients. Older age (odds ratio [OR], 1.2; 95% CI, 1.1-1.2), advanced T stage (OR, 3.5; 95% CI, 0.9-14.0), and positive margins (OR, 10.9; 95% CI, 1.8-67.5) were associated with increased regional recurrence. Extranodal extension (OR, 0.2; 95% CI, 0.04-0.8), lymph node size greater than 3 cm (OR, 0.2; 95% CI, 0.1-0.7), and adjuvant therapy (OR, 0.08; 95% CI, 0.02-0.4) were associated with decreased regional recurrence. Advanced comorbidities (hazard ratio, 6.20; 95% CI, 1.4-27.7), lymphovascular invasion (hazard ratio, 4.7; 95% CI, 1.0-21.2), and regional recurrence (hazard ratio, 16.0; 95% CI, 3.1-82.0) were associated with worse overall survival. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that patients with HPV-related OPSCC and single-node disease undergoing surgical resection with or without adjuvant treatment have excellent survival. Adjuvant therapy appears to improve regional control. Among patients with regional recurrence of OPSCC, there is a high rate of successful salvage treatment.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Chen SY, Sinha P, Last A, et al. Outcomes of Patients With Single-Node Metastasis of Human Papillomavirus-Related Oropharyngeal Cancer Treated With Transoral Surgery. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33151273. doi:10.1001/jamaoto.2020.3870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。